AC Immune (NASDAQ:ACIU) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of AC Immune (NASDAQ:ACIU) from a hold rating to a sell rating in a report released on Saturday morning.

A number of other research analysts have also recently issued reports on ACIU. Weiss Ratings reissued a “sell (d-)” rating on shares of AC Immune in a research note on Wednesday, January 21st. BTIG Research reaffirmed a “buy” rating and issued a $8.00 target price on shares of AC Immune in a report on Tuesday, November 4th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $10.00.

AC Immune Stock Performance

ACIU opened at $3.19 on Friday. AC Immune has a 52-week low of $1.43 and a 52-week high of $4.00. The firm has a market cap of $320.31 million, a P/E ratio of -3.80 and a beta of 1.62. The business’s fifty day moving average is $3.21 and its 200-day moving average is $2.87.

AC Immune (NASDAQ:ACIU) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.02. AC Immune had a negative net margin of 1,642.89% and a negative return on equity of 84.32%. The business had revenue of $1.18 million during the quarter, compared to analysts’ expectations of $0.81 million. On average, research analysts predict that AC Immune will post -0.62 earnings per share for the current fiscal year.

Institutional Investors Weigh In On AC Immune

Institutional investors have recently added to or reduced their stakes in the business. Private Advisor Group LLC bought a new position in shares of AC Immune during the third quarter valued at $48,000. Susquehanna International Group LLP bought a new position in AC Immune during the 3rd quarter worth $63,000. Sei Investments Co. acquired a new position in AC Immune during the 2nd quarter worth about $51,000. Assenagon Asset Management S.A. bought a new stake in shares of AC Immune in the 3rd quarter valued at about $549,000. Finally, Acadian Asset Management LLC grew its position in shares of AC Immune by 87.1% in the 1st quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock valued at $679,000 after buying an additional 172,796 shares during the last quarter. 51.36% of the stock is owned by institutional investors.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.